Form 8-K · Current Report · Filed 2024-01-18
BridgeBio Pharma Enters into $500M Funding Agreement and Refinances Existing Loan
BridgeBio Pharma, Inc. has entered into a Funding Agreement with LSI Financing 1 Designated Activity Company and CPPIB Credit Europe S.à r.l., under which the Purchasers will pay the Company $500 million upon the first FDA approval of acoramidis. In return, the Purchasers will receive 5% of the global Net Sales of acoramidis as Royalty Interest Payments. The Company also entered into a Financing Agreement with certain subsidiaries, lenders, and Blue Owl Capital Corporation, providing for a senior secured credit facility of up to $750 million. Additionally, the Company terminated its Existing Loan Agreement, dated November 17, 2021, by repaying all outstanding principal and accrued interest.
- Filer
- BridgeBio Pharma Inc. BBIO · NASDAQ
- Filed
- Accession
- 0001140361-24-002636
- CIK
- 0001743881
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Entry into a Material Definitive Agreement
Termination of a Material Definitive Agreement
Creation of a Direct Financial Obligation
Market reaction
Close before filing
$36.91
Next session
-0.7%
Since filing
+117.0%
Latest close
$80.09
What happened, not what will happen — closing prices around the filing date.
About BridgeBio Pharma Inc.
BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.
Never miss another BBIO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.